R&D
Project | Basic Research | Animal PoC | Non-clinical | Phase 1 | Phase 2 | Phase 3 | BLA | Remarks |
---|---|---|---|---|---|---|---|---|
HS-101 OA |
|
Intra-Articular | ||||||
HS-401 COPD |
|
Inhalation | ||||||
HS-201 Skin Aging |
|
Intradermal | ||||||
HS-301 Hair Loss |
|
Intradermal |
Selective activation of Smad2/3 signaling pathway
Efficacy in OA symptom relief and cartilage recovery
Under development as a promising DMOAD (Disease-Modifying OA Drugs) candidate
Induce the restoration of regenerative capacity by the synthesis of normal elastin fibers in alveoli and bronchial tissues and by the promotion of self-assembly
Under development as a promising fundamental therapy by inhibiting chronic inflammation and airway obstruction, as well as normalizing lung function through tissue regeneration
Normalizing damaged and reduced skin cells/tissues due to aging by strengthening the extracellular matrix through the cell biological aging mechanism
Improvement and treatment of aging skin such as wrinkles expected by strengthening the extracellular matrix and normalizing senescent cells
Regeneration and restoring effect based on the biological mechanism on aging skin that lost elasticity and wrinkled due to natural aging and exposure to light
Improvement in hair loss of various causes by restoring degenerative/damaged extracellular matrix in hair follicles
Restoring the signaling pathways in HHGMCs with HAPLN1 that is highly expressed in the hair growth phases
Developing as a hair loss treatment applicable to hair loss of various causes such as aging, stress, and hormonal abnormalities